ARTICLE | Clinical News
Blisibimod: Ph III CHABLIS-SC1 data
December 1, 2016 11:41 AM UTC
Top-line data from the double-blind, international Phase III CHABLIS-SC1 trial in about 442 patients with SLE despite ongoing stable corticosteroid therapy showed that once-weekly subcutaneous blisibi...
BCIQ Target Profiles